Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AA, abated, absolute, accommodate, adjudication, adjuvant, Adv, aftermath, agonist, AI, AICPA, akin, alanine, Alvogen, amortized, Analg, ancillary, Andrew, Anesth, Ann, antibacterial, antimicrobial, artificial, Asia, assemble, ATM, Authorea, autism, bacteria, bacterial, bactericidal, Bacteriol, bacteriostatic, Baisa, Baker, Behav, belief, binary, Biochem, Biochemistry, bioRxiv, biosynthetic, Bloch, Blvd, Boand, Boca, Br, Broth, Brown, Burch, Canadian, Chahine, CI, CIPO, Ciprofloxacin, Clin, Colesare, coli, Colistin, Colle, commonplace, complement, Compton, concordance, confronted, constraint, contamination, coupled, coupon, CPAConnect, Crit, CSF, Cucchiaro, cUTI, cutoff, cybersecurity, Datta, Davila, Decade, disconnected, discordance, discretionary, disposal, distance, Dougherty, EB, EH, electroshock, enormously, environmental, Enzymatic, EPO, equitable, Escherichia, Esq, EW, exceptionally, extrapulmonary, Fairbrother, Fax, FC, Feinberg, fell, FondaMental, FY, Gangwisch, Garrett, GDP, Gelfin, Gentamicin, Glutamatergic, Graph, Halberstam, HAMD, Hamilton, Hanania, Herrold, Hinton, Hong, illegal, importantly, impractical, incidence, incident, inconsistent, inhibitory, insert, Int, inter, interrater, interview, IRR, JA, Janet, JB, JC, JD, JL, JM, Jollant, JT, KA, Kamp, Kane, kidney, kill, Kobak, Kong, Korczykowski, Kubik, Lafayette, lag, Leboyer, Lett, licensure, lifesaving, ligand, lock, lockdown, Loebel, lt, Luthin, Lyon, male, mandatorily, Manyak, Marion, markup, MDPI, mechanistic, Ment, microorganism, MJ, MM, Monahan, mortar, MPH, MT, Mueller, Muller, multidrug, naked, neuropathic, Neuropsychopharmacol, Neurosci, Neuroscience, Nguyen, NIST, nonlethal, Northwestern, ns, NW, older, outpacing, Overallotment, overcome, overly, Panicucci, paper, Parsolex, peptidoglycan, permanent, Pharma, Pharmacother, pharmacotherapy, Phone, poor, privileged, problem, prone, provoke, psychometric, psychopathologic, Psychopharmacol, QIDP, racemase, randomised, rater, Raton, reconfigured, refinance, refinancing, Rehnquist, RP, RPM, RR, RW, SAB, salberg, Sapko, satisfactorily, Shanghai, Sharp, Sharpe, shock, Silva, sincerely, specialist, SpecPharma, spin, split, spun, squeeze, SSRN, Stabo, steadily, Stephen, strike, stubborn, subanesthetic, Surgery, Synthetase, synthetic, systematic, Szegedi, Thase, Ther, Thornby, thousand, threat, ticker, tied, tightened, TML, Tobramycin, Toll, top, Torbey, Toxicol, tract, trailing, transferrable, transient, unanimously, unaudited, unaware, unchanged, unconditional, unconditionally, underwritten, unrecruitable, unregistered, unreliability, urinary, urine, Urol, urology, UTI, van, Vania, variable, veteran, Wainwright, wall, waste, Welch, WF, Willard
Financial report summary
?Management Discussion
- For the year ended December 31, 2023, NRx Pharmaceuticals recorded $13.4 million of research and development expenses compared to approximately $17.0 million for the year ended December 31, 2022. The decrease of $3.6 million is related primarily to a decrease of $2.1 million in clinical trials and development expenses related to ZYESAMI, $1.0 million related to fees paid to regulatory and process development consultants, $0.8 million related to stock-based compensation, $0.1 million in other regulatory and process development costs, partially offset by an increase of $0.2 related to licensure of a US Patent with Apkarian Technologies, and less than $0.1 million in shipping, freight, and delivery costs. The research and development expenses for the years ended December 31, 2023 and 2022, respectively, include ($0.2) million and $0.6 million, respectively, of non-cash stock-based compensation.